Sanofi-Synthelabo and Aventis, In the Matter of

Last Updated:
In the Matter of Sanofi-Synthelabo and Aventis
FTC Matter/File Number:

041 0031

Docket Number:


Enforcement Type:

Part 2 Consents

Case Summary

The consent order settled antitrust concerns that Sanofi's proposed $64 billion acquisition of Aventis would create significant overlaps in several markets for pharmaceutical products while creating the world's third largest pharmaceutical company. Under terms of the consent order, Sanofi must: 1) divest its Arixtra factor Xa inhibitor to GlaxoSmithKline, plc; 2) divest its key clinical studies for the Campto® cytotoxic colorectal cancer treatment to Pfizer, Inc. and 3) divest Aventis' contractual rights to the Estorra insomnia drug either to Sepracor, Inc. or to another Commission-approved buyer.